胃癌中介细胞干细胞通过调节PI3K/AKT通路,在CD8T细胞上调节PD-1表达
Weimeng Ji1, Juan Xu2, Chao Huang3
1Institute of Digestive Diseases, Jiangsu University, Zhenjiang, Jiangsu 212001, China; Department of Oncology, Affiliated Hospital of Jiangsu University, Jiangsu University, Zhenjiang, Jiangsu 212001, China; School of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang, Jiangsu 212013, China.
Molecular immunology
|January 27, 2025
概括
胃癌介质干细胞 (GC-MSCs) 通过减少CD8+T细胞和增加PD-1表达来抑制抗瘤免疫力. 这些发现突出了GC-MSCs.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 胃癌介质干细胞 (GC-MSCs) 显著影响胃瘤微环境 (TME).
- GC-MSCs在建立免疫抑制环境中发挥着关键作用,促进胃癌的进展.
研究的目的:
- 研究GC-MSCs对来自胃癌患者和健康捐赠者的外周血液单核细胞 (PBMCs) 的影响.
- 阐明GC-MSCs在TME内调节免疫细胞功能的机制.
主要方法:
- 从胃癌患者和健康个体通过直接细胞与细胞接触,与胃癌患者和健康个体的PBMC共同培养GC-MSC.
- 流细胞计分析CD8+T细胞百分比和PD-1表达.
- 西部涂抹测试用于评估PBMC中的酸化AKT水平.
主要成果:
- 与GC-MSC共同培养降低了CD8+T细胞百分比,并在这些细胞上增加了PD-1表达.
- 经GC-MSC调节的介质 (GC-MSC-CM) 并没有诱导PBMC的显著变化.
- 西方斑点检测显示,在共同培养的PBMC中,酸化AKT水平下降.
结论:
- GC-MSCs通过上调CD8+T细胞的PD-1并阻碍它们的细胞毒性活动来损害抗瘤免疫反应.
- 在胃瘤微环境中,GC-MSCs有助于免疫抑制.
- 细胞间直接接触对于GC-MSC介导的免疫调节至关重要.
更多相关视频
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Mesenchymal Stem Cells
4.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K
Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


